Astria Therapeutics (NASDAQ:ATXS) Releases Earnings Results, Misses Expectations By $0.13 EPS

Astria Therapeutics (NASDAQ:ATXS) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.13), Zacks reports.

Astria Therapeutics Trading Up 0.2%

ATXS stock traded up $0.02 during midday trading on Wednesday, hitting $12.53. The stock had a trading volume of 1,324,097 shares, compared to its average volume of 741,429. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.72. The firm has a market capitalization of $707.07 million, a price-to-earnings ratio of -6.24 and a beta of 0.21. The stock has a 50-day simple moving average of $9.55 and a 200 day simple moving average of $7.07.

Institutional Trading of Astria Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its position in shares of Astria Therapeutics by 317.3% in the 1st quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company’s stock worth $582,000 after purchasing an additional 82,805 shares during the last quarter. Rhumbline Advisers increased its stake in Astria Therapeutics by 18.2% in the second quarter. Rhumbline Advisers now owns 75,674 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 11,663 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Astria Therapeutics by 8.3% during the second quarter. American Century Companies Inc. now owns 56,442 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 4,335 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Astria Therapeutics in the 2nd quarter valued at $194,000. Finally, Hsbc Holdings PLC grew its holdings in shares of Astria Therapeutics by 85.5% in the 2nd quarter. Hsbc Holdings PLC now owns 60,851 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 28,043 shares during the period. 98.98% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ATXS shares. Citigroup restated an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Astria Therapeutics in a research report on Wednesday, October 8th. Wedbush set a $13.00 price objective on shares of Astria Therapeutics and gave the company a “neutral” rating in a research report on Wednesday, October 15th. HC Wainwright downgraded shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Finally, Oppenheimer lowered shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $25.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.